Thursday, April 11, 2019 5:44:06 AM
And maybe that’s what potential new investors should do: “run and find something else”.
I don’t know. Maybe I should as well, but I’ve invested too much paying with my emotional wallet to get out.
Also, the science is just too great, the potential reward so huge, that I would be a fool to get out.
On the other hand, I feel this company is in the hands of someone I don’t (really) trust and having no real skin in the game (as he hasn’t bought on the open market using his own money).
That distrust is well earned, timelines are constantly missed, numbers are always exagerated, always implying something substantial is just around the corner, 2-4$ share price in near future, uplisting, trials soon to be started, contract negotiations, bragging about the Paulson raises, how supportive they’ve been. Should I continue? This list can be endless.
One reason for an increase in share price is competent and trustworthy management. I doubt we can check that box. Meanwhile he’s getting paid very nicely. He just got a raise and now they’re asking to increase the number of shares in benefit of the share incentive plan. Why is that? What has been accomplished? I’m all for rewarding someone that caused my wealth to grow (increased share price). As long as anything accomplished isn’t reflected in a share price increase there should be no extra rewardation.
Potential investors should know that if they decide to invest in Cydy they’re investing in one of the most exciting and promising companies out there but also that they’re going to enter a world of pain, because anything said simply can not be relied upon.
Not shorting, being very long but also feeling very frustrated.
I don’t know. Maybe I should as well, but I’ve invested too much paying with my emotional wallet to get out.
Also, the science is just too great, the potential reward so huge, that I would be a fool to get out.
On the other hand, I feel this company is in the hands of someone I don’t (really) trust and having no real skin in the game (as he hasn’t bought on the open market using his own money).
That distrust is well earned, timelines are constantly missed, numbers are always exagerated, always implying something substantial is just around the corner, 2-4$ share price in near future, uplisting, trials soon to be started, contract negotiations, bragging about the Paulson raises, how supportive they’ve been. Should I continue? This list can be endless.
One reason for an increase in share price is competent and trustworthy management. I doubt we can check that box. Meanwhile he’s getting paid very nicely. He just got a raise and now they’re asking to increase the number of shares in benefit of the share incentive plan. Why is that? What has been accomplished? I’m all for rewarding someone that caused my wealth to grow (increased share price). As long as anything accomplished isn’t reflected in a share price increase there should be no extra rewardation.
Potential investors should know that if they decide to invest in Cydy they’re investing in one of the most exciting and promising companies out there but also that they’re going to enter a world of pain, because anything said simply can not be relied upon.
Not shorting, being very long but also feeling very frustrated.
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
